U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H17N3O2S
Molecular Weight 291.369
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FASUDIL

SMILES

O=S(=O)(N1CCCNCC1)C2=CC=CC3=C2C=CN=C3

InChI

InChIKey=NGOGFTYYXHNFQH-UHFFFAOYSA-N
InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2

HIDE SMILES / InChI

Molecular Formula C14H17N3O2S
Molecular Weight 291.369
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Fasudil is a potent Rho kinase inhibitor, which was developed by Asahi Kasei. The drug is used in Asia for the prevention of cerebral vasospasm in patients with subarachnoid hemorrhage.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.4 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
ERIL

Approved Use

Improvement of cerebral vasospasm and cerebral ischemic symptoms associated with cerebral vasospasm after subarachnoid hemorrhage.
PubMed

PubMed

TitleDatePubMed
Combined administration of Fasudil hydrochloride and nitroglycerin for treatment of cerebral vasospasm.
2001
Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm after subarachnoid hemorrhage.
2001 Apr
Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans.
2001 Dec 1
Rho-associated kinase phosphorylates MARCKS in human neuronal cells.
2001 Jan 26
Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo.
2001 Jul
Antiischemic properties of fasudil in experimental models of vasospastic angina.
2001 Sep
Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina.
2002 Apr 2
RhoA kinase and protein kinase C participate in regulation of rabbit stomach fundus smooth muscle contraction.
2002 Dec
Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study.
2002 Nov
Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats.
2002 Nov 22
Occupation of the prostaglandin E2-type 1 receptor increases rat atrial contractility via a Y-27632-sensitive pathway.
2002 Sep
Functional roles of the rho/rho kinase pathway and protein kinase C in the regulation of cerebrovascular constriction mediated by hemoglobin: relevance to subarachnoid hemorrhage and vasospasm.
2003 Apr 18
Rho kinase inhibitors block activation of pancreatic stellate cells.
2003 Dec
A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat.
2003 Jan 3
Astrocyte stellation induced by Rho kinase inhibitors in culture.
2003 Jun 12
Vessel- and vasoconstrictor-dependent role of rho/rho-kinase in renal microvascular tone.
2003 May-Jun
Expression of Rho-kinase and its functional role in the contractile activity of the mouse vas deferens.
2003 Oct
Effects of HA-1077 and Y-27632, two rho-kinase inhibitors, in the human umbilical artery.
2004
Regulation of osteoblast differentiation by Pasteurella multocida toxin (PMT): a role for Rho GTPase in bone formation.
2004 Apr
[Development of drug delivery system for intrathecal administration and its therapeutic effect on cerebral vasospasm and ischemia].
2004 Aug
Involvement of Rho-kinase in cold ischemia-reperfusion injury after liver transplantation in rats.
2004 Aug 15
Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina.
2004 Aug 20
Differential effects of Rho-kinase inhibition on artery wall mass and remodeling.
2004 Jan
Inhibition of protein kinase C-mediated contraction by Rho kinase inhibitor fasudil in rabbit aorta.
2004 Nov
[Inhibition of Rho-kinase by fasudil preventing anginal attacks associated with spastic angina: a case report].
2004 Oct
Expression of Rho-kinase (ROCK-1 and ROCK-2) and its substantial role in the contractile activity of the sheep ureter.
2004 Oct
Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection.
2004 Oct
Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery.
2004 Sep
Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats.
2004 Sep
Mechanisms underlying postjunctional synergism between responses of the vas deferens to noradrenaline and ATP.
2004 Sep 13
Therapeutic potential of rho-kinase inhibitors in cardiovascular diseases.
2005
Long term Rho-kinase inhibition ameliorates endothelial dysfunction in LDL-Receptor deficient mice.
2005 Apr 11
Rho-kinase and myosin II activities are required for cell type and environment specific migration.
2005 Feb
Prostacyclin does not inhibit rho-kinase: an implication for the treatment of pulmonary hypertension.
2005 Feb
[Role of calcium desensitization in vascular hyporeactivity in hemorrhagic shock].
2005 Jan
Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes.
2005 Jul
Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats.
2005 May
Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis.
2005 May 3
Patents

Sample Use Guides

The recommended dosage is 30 mg fasudil hydrochloride should be diluted in 50-100 mL solution and administered by intravenous infusion over 30 minutes 2-3 times daily.
Route of Administration: Intravenous
The rat aortic rings were contracted by KCl; when the contraction reached a plateau, fasudil was added at concentrations from 10(-9) to 10(-5) M. The relaxation IC50 was 0.74 uM. When rabbit aortic rings were used, IC50 values were 37,15 uM and 27,54 uM for KCl and Methoxamine-induced contraction, respectively.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:55:02 GMT 2023
Edited
by admin
on Sat Dec 16 16:55:02 GMT 2023
Record UNII
Q0CH43PGXS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FASUDIL
INN   MI   WHO-DD  
INN  
Official Name English
AT-877
Code English
HA 1077
Code English
1-(5-ISOQUINOLINESULFONYL)HOMOPIPERAZINE
Systematic Name English
HA-1077
Code English
HEXAHYDRO-1-(5-ISOQUINOLYLSULFONYL)-1H-1,4-DIAZEPINE
Systematic Name English
ZK-258594
Code English
N-(5-ISOQUINOLINESULFONYL)-1,4-PERHYDRODIAZEPINE
Common Name English
fasudil [INN]
Common Name English
ISOQUINOLINE, 5-((HEXAHYDRO-1H-1,4-DIAZEPIN-1-YL)SULFONYL)-
Systematic Name English
FASUDIL [MI]
Common Name English
AT 877
Code English
NSC-759827
Code English
5-((HEXAHYDRO-1H-1,4-DIAZEPIN-1-YL)SULFONYL)ISOQUINOLINE
Systematic Name English
Fasudil [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC C04AX32
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
FDA ORPHAN DRUG 787220
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
NCI_THESAURUS C1404
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
FDA ORPHAN DRUG 719119
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
WHO-VATC QC04AX32
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
FDA ORPHAN DRUG 700019
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
FDA ORPHAN DRUG 761320
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID4048569
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
IUPHAR
5181
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
MERCK INDEX
m5249
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY Merck Index
DRUG CENTRAL
1132
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
EVMPD
SUB07515MIG
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
SMS_ID
100000081784
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
NSC
759827
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
PUBCHEM
3547
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
WIKIPEDIA
FASUDIL
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
ChEMBL
CHEMBL38380
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
DRUG BANK
DB08162
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
INN
6696
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
NCI_THESAURUS
C65624
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
FDA UNII
Q0CH43PGXS
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
CAS
103745-39-7
Created by admin on Sat Dec 16 16:55:03 GMT 2023 , Edited by admin on Sat Dec 16 16:55:03 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY